Articles by Keyword for

  Pradaxa is currently the only FDA approved drug that inhibits factor Xa and seems to have significant advantages over Coumadin. Early studies have shown a 21% less likely risk of stroke in atrial fibrillation, a 31% lower risk of bleeding, and an 11% lower mortality rate. Two drugs under study by the FDA now include Xarelto, and Eliquis.  If...

  A large clinical trial testing the effects of aspirin and Plavix to prevent small strokes was stopped because there was no added benefit by combining these drugs and the risk of bleeding was too high. This information was presented at the 2012 American Stroke Association meeting in February of 2012. A second abstract presented at the same conference...